- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05828134
Enhancing Muscle Health and Metabolism in Pre-frail Middle-aged and Older Adults
Enhancing Muscle Health and Metabolism in Pre-frail Middle-aged and Older Adults: A Randomized Controlled Trial Investigating the Benefits of Protein-enriched Supplementation and Weekly Exercise
To evaluate the effects of protein-enriched soup plus exercise on muscle mass and muscle strength.
Besides, the investigators use the valued-based healthcare standard set as well as the Center for Epidemiological Studies-Depression, Charlson's comorbidity index Montreal Cognitive Assessment , and Mini Nutritional Assessment as outcome measures and to use the trial in validate additional supplement protein-enriched soup plus exercise could improve the vitality and health of mid-aged and old adults.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Taipei, Taiwan
- National Yang Ming Chiao Tung University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- People who aged 50-75 years
- Patients with following characteristics:
- feeling loss in activity
- detecting decline in self's walking speed.
- feeling tired of doing everything.
- having fell in last year.
- People willing to follow the program and cooperate with us for following tracking.
- People who are neither vegan nor vegetarian
- People agree and be able to sign the informed consent.
- the protein of the daily meal are less than 1.0g/kg
Exclusion Criteria:
- People cannot intake provided meals (e.g.: vegans or vegetarians) or any other who is allergic to our diets.
- People with any disease affecting their limbs, including:
- having fracture on limbs in the past 6 months
- having severe arthritis in the past 6 months
- any other whom PI recognized as weak control of their nervous system( e.g.: Parkinson's disease and stroke).
- People with intermittent limp caused by peripheral artery diseases
- People with weak control of mental disorder
- People with weak control of Cardiopulmonary disease
- People with weak control of Malignant tumor
- People with weak control of kidney diseases (eGFR <60ml/min/1.73)
- People with Visual impairment and Hearing disorder which cannot help to complete the program.
- People who have underwent hormone treatment and planned to undergo hormone treatment during program session.
- Any other condition that PI recognized as not suitable
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
No Intervention: Usual care group
The control group only performed routine data collection and gave them dietary suggestion.
|
|
|
Experimental: Protein-enriched soup group
Protein-enriched soup /day for use as a supplement with meals and strength training /week
|
The participants in experimental group have a protein-enriched soup a day and do exercise a week
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes from baseline physical function after 12 weeks
Time Frame: baseline, 4, 12 weeks
|
measured by hand grip, 6-minute walk distance, six-meter walking speed, 5 times sit-to-stand
|
baseline, 4, 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes form baseline QUALITY OF LIFE after 12 weeks
Time Frame: baseline, 4, 12 weeks
|
measured by the 36-Item Short Form Health Survey (SF-36), ranged 0-100, higher values represent a better condition
|
baseline, 4, 12 weeks
|
|
Change from baseline Nutrition intake after 12 weeks
Time Frame: baseline, 4, 12 weeks
|
measured by Mini-nutritional assessment questionnaire.
ranged 0-30, higher values represent a better condition
|
baseline, 4, 12 weeks
|
|
Change from baseline depression after 12 weeks
Time Frame: baseline, 4, 12 weeks
|
measured by the Center for Epidemiological Studies-Depression (CES-D) ranged 0-60, higher values represent a worse condition
|
baseline, 4, 12 weeks
|
|
Change from baseline cognitive ability after 12 weeks
Time Frame: baseline, 4, 12 weeks
|
measured by Montreal Cognitive Assessment (MoCA) , ranged 0-30, higher values represent a better condition
|
baseline, 4, 12 weeks
|
|
Change from baseline body composition analysis after 12 weeks
Time Frame: baseline, 4, 12 weeks
|
measured by RASM
|
baseline, 4, 12 weeks
|
|
Change from baseline concentration of Total Cholesterol after 12 weeks
Time Frame: baseline, 4, 12 weeks
|
Change from baseline concentration of Total Cholesterol after 12 weeks
|
baseline, 4, 12 weeks
|
|
Change from baseline concentration of Triglyceride after 12 weeks
Time Frame: baseline, 4, 12 weeks
|
Change from baseline concentration of Triglyceride after 12 weeks
|
baseline, 4, 12 weeks
|
|
Change from baseline concentration of high-density lipoprotein cholesterol after 12 weeks
Time Frame: baseline, 4, 12 weeks
|
Change from baseline concentration of high-density lipoprotein cholesterol after 12 weeks
|
baseline, 4, 12 weeks
|
|
Change from baseline concentration of low-density lipoprotein cholesterol after 12 weeks
Time Frame: baseline, 4, 12 weeks
|
Change from baseline concentration of low-density lipoprotein cholesterol after 12 weeks
|
baseline, 4, 12 weeks
|
|
Change from baseline concentration of dehydroepiandrosterone after 12 weeks
Time Frame: baseline, 4, 12 weeks
|
Change from baseline concentration of dehydroepiandrosterone after 12 weeks
|
baseline, 4, 12 weeks
|
|
Change in International Physical Activity Questionnaire (IPAQ) after 12 weeks
Time Frame: baseline, 4, 12 weeks
|
Change in physical activity measured by IPAQ, indicates that spent being physically active thin the prior 7 days.There are no established thresholds for presenting MET-minutes, the IPAQ Research Committee proposes that reported as comparisons of median values and interquartile ranges for different populations from baseline to 12 weeks in all participants.
|
baseline, 4, 12 weeks
|
|
Change from baseline numbers of Complete blood count after 12 weeks
Time Frame: baseline, 4, 12 weeks
|
Change from baseline numbers of Complete blood count after 12 weeks
|
baseline, 4, 12 weeks
|
|
Change from baseline concentration of Albumin after 12 weeks
Time Frame: baseline, 4, 12 weeks
|
Change from baseline concentration of Albumin after 12 weeks
|
baseline, 4, 12 weeks
|
|
Change from baseline concentration of Alanine Aminotransferase (ALT) after 12 weeks
Time Frame: baseline, 4, 12 weeks
|
Change from baseline concentration of Alanine Aminotransferase (ALT) after 12 weeks
|
baseline, 4, 12 weeks
|
|
Change from baseline concentration of Aspartate Aminotransferase (AST) after 12 weeks
Time Frame: baseline, 4, 12 weeks
|
Change from baseline concentration of Aspartate Aminotransferase (AST) after 12 weeks
|
baseline, 4, 12 weeks
|
|
Change from baseline concentration of blood urea nitrogen after 12 weeks
Time Frame: baseline, 4, 12 weeks
|
Change from baseline concentration of blood urea nitrogen after 12 weeks
|
baseline, 4, 12 weeks
|
|
Change from baseline concentration of Creatinin after 12 weeks
Time Frame: baseline, 4, 12 weeks
|
Change from baseline concentration of Creatinin after 12 weeks
|
baseline, 4, 12 weeks
|
|
Change from baseline concentration of Fasting glucose after 12 weeks
Time Frame: baseline, 4, 12 weeks
|
Change from baseline concentration of Fasting glucose after 12 weeks
|
baseline, 4, 12 weeks
|
|
Change from baseline concentration of Fasting insulin after 12 weeks
Time Frame: baseline, 4, 12 weeks
|
Change from baseline concentration of Fasting insulin after 12 weeks
|
baseline, 4, 12 weeks
|
|
Change from baseline concentration of high-sensitivity C-reactive protein after 12 weeks
Time Frame: baseline, 4, 12 weeks
|
Change from baseline concentration of high-sensitivity C-reactive protein after 12 weeks
|
baseline, 4, 12 weeks
|
|
Change from baseline concentration of 25-(OH)-Vit. D after 12 weeks
Time Frame: baseline, 4, 12 weeks
|
Change from baseline concentration of 25-(OH)-Vit.
D after 12 weeks
|
baseline, 4, 12 weeks
|
|
Change from baseline concentration of Leptin after 12 weeks
Time Frame: baseline, 4, 12 weeks
|
Change from baseline concentration of Leptin after 12 weeks
|
baseline, 4, 12 weeks
|
|
Change from baseline concentration of urine protein after 12 weeks
Time Frame: baseline, 4, 12 weeks
|
Change from baseline concentration of urine protein after 12 weeks
|
baseline, 4, 12 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Liang-Kung Chen, MD.PhD., Center for Healthy Longevity and Aging Sciences, National Yang Ming Chiao Tung University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- YM109172F
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Muscle Weakness
-
St. Luke's-Roosevelt Hospital CenterCompletedFall Risk | Quadriceps Muscle Weakness | Adductor Muscle WeaknessUnited States
-
Eastern Mediterranean UniversityCompletedPelvic Floor Muscle WeaknessCyprus
-
Lactomason Co., Ltd.RecruitingAge-Related Muscle WeaknessSouth Korea
-
Healthbiome IncCompletedAge-Related Muscle WeaknessSouth Korea
-
Association Pro-arteActive, not recruitingWeakness, Muscle | AmyotrophiaFrance
-
University of Central ArkansasCompletedPelvic Floor Muscle WeaknessUnited States
-
Rutgers, The State University of New JerseyRecruitingPhysical Disability | Muscle Atrophy or Weakness | Muscle Loss | Physical Inactivity | Delirium in Old Age | Hospital Acquired Condition | Weakness, MuscleUnited States
-
Spitalul Clinic de Boli Infecțioase și Pneumoftiziologie...CompletedMuscle Weakness | Muscle Weakness Condition | CopdRomania
-
Ludwig Boltzmann Institute of Electrical Stimulation...Medical University of Vienna; European Union; Comenius University; Ministry of...CompletedMuscle Weakness Condition | Therapy EffectAustria, Slovakia
-
University of Texas Southwestern Medical CenterTerminatedMuscle Cramp | Statin Adverse Reaction | Weakness, Muscle | AcheUnited States
Clinical Trials on protein-enriched soup
-
Ajinomoto Co., Inc.CompletedNutrition InterventionUnited States
-
Hospital General Universitario Gregorio MarañonInstituto de Salud Carlos III; European Regional Development Fund; Maternal,...UnknownProtein-Energy MalnutritionSpain
-
Unity Health TorontoCompleted
-
Mead Johnson NutritionCompletedCognitive Ability, GeneralChina
-
Clinica Universidad de Navarra, Universidad de...CompletedObesity | Weight Loss | ProteinSpain
-
Mead Johnson NutritionShanghai Children's Medical CenterCompletedCognitive Ability, GeneralChina
-
Wageningen UniversityCompletedUndernutritionNetherlands
-
Puleva BiotechUniversidad de GranadaUnknown
-
Université Catholique de LouvainUniversity of Liege; University of MonsCompletedHealthy VolunteersBelgium
-
Paul PoirierCompletedType 2 Diabetes | Glycemic ResponseCanada